Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) announced an investor webcast on May 26, 2026 at 8:30 a.m. Eastern to review Q1 2026 financials and provide corporate updates. The company also plans to file its Form 10-Q for the quarter ended March 31, 2026 on May 20, 2026.
CEO Lisa Conte will present virtually at the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 at 10 a.m. Eastern. Replays of both events will be available online.
Positive
- None.
Negative
- None.
News Market Reaction – JAGX
In the May 20 session, JAGX gained 9.39%, reflecting a notable positive market reaction. Argus tracked a peak move of +49.2% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Q3 2025 earnings | Neutral | +1.4% | Reported Q3 2025 revenue growth with ongoing net loss and EBITDA pressure. |
| Nov 14 | Earnings webcast notice | Neutral | +4.7% | Announced Form 10-Q filing timing and Q3 2025 investor webcast schedule. |
| Aug 14 | Q2 2025 earnings | Positive | -20.1% | Reported strong Q2 2025 revenue growth and higher Mytesi volume despite wider loss. |
| May 15 | Q1 2025 earnings | Negative | -10.9% | Q1 2025 revenue declined and net loss widened compared with prior periods. |
| May 14 | Earnings webcast notice | Neutral | -6.5% | Scheduled Q1 2025 webcast and outlined Form 10-Q filing plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related news has historically produced an average move of -6.27%, with several prior quarters seeing downside despite operational updates.
Recent earnings-linked events for Jaguar show mixed fundamentals alongside generally negative price reactions. Q1 and Q2 2025 results featured revenue pressure and widening losses, and shares fell double-digits after both. Later, Q2 and Q3 2025 results highlighted revenue growth and Mytesi prescription gains but still involved sizable net losses. Webcast announcements around filings, such as in May 2025 and November 2025, drew smaller, mixed reactions. Today’s Q1 2026 webcast notice fits this pattern of frequent communications around quarterly filings.
Key Terms
form 10-q regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference
Company plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the quarter ended March 31, 2026
SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 26, 2026 at 8:30 a.m. Eastern to review first-quarter 2026 financials and provide corporate updates, and that Lisa Conte, Jaguar's founder, president and CEO, will present virtually on Thursday, May 28, 2026 at 10 a.m. Eastern at the Lytham Partners Spring 2026 Investor Conference.
Participation Instructions for Jaguar Health Investor Webcast
When: Tuesday, May 26, 2026 at 8:30 a.m. Eastern
Participant Registration & Access Link: Click Here
Replay: A replay of the webcast will be available on the investor relations section of Jaguar's website: (click here)
Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Spring 2026 Investor Conference
When: Thursday, May 28, 2026 at 10 a.m. Eastern
Registration link for conference: Click Here
Replay: A replay of the webcast will be available through the same link (click here)
About the Jaguar Health Family of Companies
Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will file its Form 10-Q on May 20, 2026 for the quarter ended March 31, 2026, the expectation that Jaguar will hold an investor webcast on May 26, 2026, and Jaguar's expectation that Jaguar management will present at the Lytham Partners Spring 2026 Investor Conference. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire